Home / Transcripts / Nanoform Finland Oyj (NANOFH) · November 12, 2025

Nanoform Finland Oyj (NANOFH) Earnings Call Transcript

November 12, 2025

Nasdaq Helsinki FI Health Care Life Sciences Tools and Services earnings 41 min

Earnings Call Speaker Segments

Operator operator
#1

Thanks for joining this conference call. <<operator_script>> At this point I’ll turn the call over to the speakers. Please go ahead.

Henri von Haartman executive
#2

Good afternoon, everyone, and a very warm welcome to the Third Quarter 2025 Report Presentation for Nanoform. I'm Henri von Haartman, Director of Investor Relations. Presenting to you today will be our CEO, Edward Haeggstrom; our Chief Quality Officer, Johanna Kause; our CFO, Albert Haeggstrom; our Chief Commercial Officer, Christian Jones; and our Chief Development Officer, Peter Hanninen. This presentation is being webcast via investor call, and you can also dial in and listen over the phone. The slides you see here can likewise be found on our web page under the Investors section. Following the presentation, we'll hold a Q&A, and questions can be asked by calling in. Today we'll begin with a brief introduction, followed by key business highlights, then financials, then commercial performance, and we'll wrap up with our product kernels. With that, I'll hand things over to our CEO, Founder, and Professor, Edward Haeggstrom — please go ahead.

Edward Haeggstrom executive
#3

Henri, thanks, and welcome from me as well. Next slide, please. So this is a commercially licensed manufacturing facility you're looking at here. That's the big news for today. We've secured a license to serve European markets as well as other ones, with a total headcount of 500 million. Next slide, please. At this point I'd like to go over our strategy again and rehearse it a bit. First of all, every active pharmaceutical ingredient ought to be Starmapped. That provides a means of seeing where we're able to make a difference. We collaborate with customers and partners so that novel and existing molecules can turn into new and improved medicines. Alongside that, we demonstrate to a conservative industry what nanoforming can do, and we achieve this by creating up to a dozen product kernels. Today we'll be talking a lot about Nanoenzalutamide, a lot about product kernels, and a little bit too about the biologic case of Elektrofi. Next slide, please. Here, essentially, we partner with originators, and those customers are large global pharma, midsized and specialty pharma, and biotechs. Working alongside them, we aim to bring nano improved drugs to the market.

Edward Haeggstrom executive
#4

The product kernels is an API that we've nanoformed, and that lets us make a commercially relevant offering. In this case, we partner with development partners. Those could be originators, or they could be super-generic, high-value medicine companies. After that, we work with commercial partners. These may be the same folks as the development partners, or they may be different. And here, as quickly as we can, we aim to bring our first nano of improved drug to market so we can demonstrate the strength of our tech platforms. Next, please. We have 4 distinct technology platforms: one for small molecules, one for large molecules, one for nano-formulation, and then STARMAP for AI. On the small molecule side, better bioavailability and high drug load are what drive the commercial cases. On the large molecule side, high drug load and long-acting delivery are what drive the commercial cases now. On the formulation side, it's obvious that highly differentiated novel formulations and unique drug delivery opportunities are what push the commercial opportunities ahead. Next slide, please. Our simplified value chain hasn't changed at all. We have our clients, and usually they own the API. We nanoform it, and then we either get paid for demonstrating that it can be done, for making material under GMP, or now, together with our partners, for moving the kernels forward.

Edward Haeggstrom executive
#5

Moving on, please. This is a timeline. A long time ago, we invented and discovered the CESS process. In 2020, we ran the first GMP campaign in a clinical setting. And now we've finally secured authorization to sell nanoformed API on the European market. And of course, the goal now is to bring the first nanoformed medicine to the European market as soon as possible. Next, please. Here, I'd like to take you through the key business highlights. The manufacturing license is obviously and clearly the most important achievement at this moment. It's not insignificant that Nancoencorafenib, as one of the kernels, has now received funding, and we've signed a licensing and development agreement with A.forall, which is part of Riverside and together with IMGA. This is a fund, and later on you'll hear more details. There's also a new kernel being introduced now, which is a nano-formulated combination of olaparib and temozolomide. And this is now announced in a partnership with Revio Therapeutics. This is a boutique player with people who have a long history in the industry and with serious financial backing. We also, right now, are introducing the first target for 2026, which is to continue our path toward cash flow positivity.

Edward Haeggstrom executive
#6

Our goal is to keep cash burn under EUR 10 million. For 2025, every one of our near-term targets remains on schedule. Also, please join us in Helsinki on December 16 for a Capital Markets Day. There, we'll present the new 2030 midterm targets, and we'll talk through them as well. Next slide, please. At this point I'll pass things over to our quality boss, Chief Quality Officer, Johanna Kause. Please.

Johanna Kause executive
#7

Thank you, Edward. Hello, everyone. Let me open this slide by saying that today is a great day for me, and I believe it is a great day as well for patients in Europe and patients around the world. We have been granted the commercial GMP manufacturing license that we worked very hard to obtain over the past years. What that means is we are now authorized to produce Nanoform small molecule APIs and to handle their quality control. That means we will be able to manufacture APIs for products that hold a marketing authorization in Europe — with a focus on Europe, but also in other regions across the globe. So this has been a really, really big thing for us, and I believe it is big on a wider scale too, because a new technology reaching this stage is not really an everyday occurrence. The next step, now that we have achieved this, is that we will keep working on the launch of the Nanoenzalutamide product. So in parallel with preparing for this commercial license, we have been creating our first active substance master file. That is a documentation package that will become part of the marketing authorization application for Nanoenzalutamide.

Johanna Kause executive
#8

Of course, the marketing authorization application process is going to be run, or managed, jointly with our consortium partners—but we play an essential role in it. And in parallel, we are, of course, striving to secure and enhance supply reliability across the entire supply chain for Nanoenzalutamide. Next slide, please. Okay. On this slide, I'll pass things over to Albert Haeggstrom, our CFO.

Albert Haeggstrom executive
#9

Thank you, Johanna. If we move to this slide here, what you’re seeing on the left-hand side is that proposals sent have really jumped during this year. There are lots of reasons behind that, but the biggest ones are that, after 4 years in which the industry was really stuck in the doldrums, it’s now clear that investors — and generics companies as well — are beginning to move, since they recognize that the technologies we offer can deliver something genuinely valuable to the industry. Signings are still being held back by the fact that biotech funding isn’t what it used to be, and also because large pharma and major pharma are currently concentrating heavily on cost cutting and on reducing their personnel rather than on the early stage of the pipeline. What’s clear is that the early stage of pipelines across the pharma industry has become thinner and thinner over the last years, because all the attention has gone to late-stage assets. But we believe that is now starting to come to an end. It can’t get any darker. So that means we believe this is also one of the reasons why we’re seeing the proposal sent go up.

Albert Haeggstrom executive
#10

Eventually, every company has to refill its early-stage pipeline, and that is our view here. So we look toward next year with optimism. On the right-hand side, you can see that even with the difficult market conditions, we have managed to keep the count of projects signed over the last 4 years fairly flat. And naturally, proposals ought to be indicative of -- or a leading indicator for what will come next year. Looking at revenue and other operating income, a similar picture appears there. But here, you can already see that this year has been stronger. And of course, on the following slide, which shows customer payments versus revenues recognized, you can see it even more clearly. So last year, the two were moving in tandem, but now it is evident that customer payments have been rising faster than revenues recognized. The reason is that when you sign an agreement, you receive the upfront payment, and we have also begun to receive the first small milestone payments. Then, when the work is completed later on, that gets recognized as revenue. So even if the top line has not reflected it yet, customer payments have grown very nicely this year.

Albert Haeggstrom executive
#11

This matters a great deal for cash flow, naturally. Our management of the business rests on cash flow rather than on revenues that get recognized. That's where you're able to observe that the quarterly cash burn trend — the annualized cash burn trend — has kept moving in a really favorable direction. Take the comparison, for instance, with the third quarter of this year: EUR 3.9 million against EUR 5.3 million a year earlier. And at this point we've been sitting at an annualized rate of approximately minus EUR 15 million. Now we're putting forward the new target for 2026, which is a cash burn below EUR 10 million across the full year. Compare that with the cash on hand at the close of the third quarter, which came to nearly EUR 30 million. So we believe we have a strong balance sheet, and we believe the trend is clearly the right one. Questions come up about where this will come from. It will come from a number of different factors: improved top line customer payments, but also we can see that we had been building the factory. We have been making the big investments. We have built done some parts the automation, and all these factors will mean that we'll also see a continued trend of lower costs going forward.

Albert Haeggstrom executive
#12

So a mix of higher income plus reduced costs works well for generating substantially stronger cash flow. Then, when we turn to the near-term targets, as Edward mentioned, every one of them remains on schedule for this year. Several have already been met, and that makes us quite pleased. After that, as I noted, the first business target for '26 was announced, namely cash burn under EUR 10 million, which you can set against the EUR 30 million in cash that we hold right now. A few additional business targets will come when we present the full year report. With that, I'll pass things to Christian and Peter on the commercial side. Thank you.

Christian Jones executive
#13

Thanks, Albert. Let's keep things moving. So the main points I want to cover with you today center on the commercial manufacturing license. What exactly does that mean? In practice, it means we've got a really solid path for bringing our partners' products to market. It gives the innovative pharma companies and biotechs we work with confidence that we have a clear route to market. And it also lets the product kernels we're developing move ahead on the timelines we've tied to them. Really good progress so far on our product kernels — enzalutamide in particular is advancing at real speed. Right now we're in our pivotal bioequivalent study, and we're very eager to see the results soon. There's some fantastic news as well on encorafenib and on a product development effort with Revio Therapeutics for glioblastoma. We'll go into more detail on that later, on the slides that follow. We've also been seeing a very strong market pull for our biologics technology — it's been considerable. And I think that's partly because small molecules have existed for a long time. There are plenty of technologies attempting to tackle the challenges, while biologics is a very new area, and only a handful of technologies can truly add value in the drug delivery space.

Christian Jones executive
#14

Nanoform's technology is viewed as one of the tools capable of playing a key part in pushing the biologics market ahead. That has been supplemented by the excellent work we have carried out with Takeda and by the fact that Takeda and Nanoform can jointly present on our results at a number of conferences. And we have managed to cover case studies for high concentration subcutaneous injection. This is a very hot area right now, and also the delivery of biologics to the lungs, an area where we see many advantages for our technology compared with other approaches. For -- up until the end of the third quarter, we had 16 customer projects. Looking at previous years, that is no mean feat in what is this year a very tough CDMO market. We have seen other peers in the CDMO space, some of the leading CDMOs in the world, who have commented that they have a very dry pipeline in this space for early development assets. We have also -- not only have we been growing our customer base in Europe and the U.S., we have also expanded into Asia as well, with great relationships established in both Japan and South Korea, key markets, but also key markets from an innovation perspective, and we look forward to further growing the business in that territory.

Christian Jones executive
#15

I'll pass things over to Peter, who will walk us through the next couple of slides.

Peter Hänninen executive
#16

Thanks, Christian, and hello everyone joining the call — I'd also like to welcome you on my behalf. Let me begin once more by recalling the strategy behind our product kernels. So that we can speed up even more the uptake of technology offerings by the industry, we've kicked off internal development of several nanoparticle-enabled reformulations. The point is to demonstrate to the industry what our technology is able to deliver for their products, spanning a range of delivery routes and covering both small and large molecules. On top of that, each one of these carries the potential to turn into a commercially appealing partnering opportunity for us in its own right. We're really happy with the way this strategy is unfolding at present and with what has been accomplished within a fairly brief stretch of time. Importantly, we've managed as well to bring experienced partners on board to help carry out several of these projects already. And the completion of the out-licensing development and commercialization agreement, together with an investment into Nancoencorafenib by A.forall and IMGA, represented a major milestone in moving this product kernels toward the clinic. That investment should be enough to fund the clinical development of Nancoencorafenib through to commercialization and the future out-licensing, whether as an appealing patient-centric lifestyle management opportunity or as a value-added generic medicine.

Peter Hänninen executive
#17

BRAFMed, the company established alongside IMGA and A.forall, will also pay Nanoform service fees, low single million development milestones, and up to mid-single-digit tiered trial payments as things move forward. Nanoform's fully diluted ownership stake in BRAFMed should come in at roughly 40% to 50%, compared with 71% as of today. During the quarter, we announced one more kernel as well — the co-development with radiotherapeutics of what we refer to as GLIORA, a locally administered long-acting thermo-responsive hydrogel intended for treating high-grade glioma. GLIORA is a nano-formulated combination of olaparib, currently marketed by AstraZeneca under the Lynparza name, and temozolomide, currently marketed as a Temodar and originally developed by Merck & Company. We're very pleased to be partnering with Revio Therapeutics on this project. They're a boutique made up of genuinely seasoned industry veterans, with their own platform for identifying repurposing opportunities and backing from strong private investors. And this gives us a highly synergistic partner for our enabling formulation technologies. That's what we can already see in this first example with GLIORA. This program is expected to reach the clinic by the second half of 2026. And we expect it could be eligible for orphan designation and accelerated approval, and therefore, subject to successful co-development and commercialization, could already be commercially available by the '29-'30 time frame.

Peter Hänninen executive
#18

When we take a look at the pipeline for our kernels as a whole, I believe it's fair to state that work on this project keeps moving forward on every front. The colleagues who joined the call have already discussed in detail why the commercial manufacturing license matters in general and, more specifically, why it stands as a milestone for the future launch of Nanoenzalutamide. And I'd say that point truly deserves emphasis. Beyond that, we are actively getting ready to begin production of the initial GMP batches of Nanoenzalutamide, with support from the EUR 5 million R&D loan provided by Business Finland. On top of this, interest in partnering on that asset continues to grow. Naturally, we also look forward to the chance to share more with you about the undisclosed kernels down the road. As a broader reflection, I would note that being able to draw seasoned specialist health care investors into backing our strategy — using Nanoform's technology to develop this nanoparticle-enabled reformulation — matters on many levels. It helps validate the strategy, and it also strengthens the message surrounding the technology while supporting commercialization of these assets. Such partners can further bring experience and expertise on regulatory, clinical and market access matters, which will directly support successful execution of the product.

Peter Hänninen executive
#19

And what I'd add is that this also lets us keep casting a wide net and working across a broad range of APIs, delivery routes and therapy areas, and it underscores how broadly applicable our particle technologies are. Christian, I think, already mentioned the recent industry news about Halozyme's acquisition of Elektrofi. But before I hand it over to Christian, a few words from me on that as well. Subcutaneous delivery, I think, is going to be a big part of the future given the obvious advantages of our IP. For higher dose products, the only meaningful technology to date has been Halozyme's uronid approach, and they've managed to build a highly successful business model around it. And as you know, Nanoform has been one of the few companies globally that has pioneered development of ultra-high concentration suspensions for subcutaneous delivery, together with companies like Elektrofi. Halozyme's acquisition of Elektrofi for up to $900 million, with $750 million upfront in cash, is a strong endorsement for this approach generally. And we believe this will continue to be an extremely interesting space as the first products using this approach and clinic. And we're confident that our platform, which was designed with scalability and robustness and patient-centric administration in mind, will be highly competitive as this new market for higher subcutaneous delivery of biologics is form.

Peter Hänninen executive
#20

So with that said, I'll hand things over to Christian so he can share his thoughts.

Christian Jones executive
#21

Thank you, Peter. I'd like to build on that point. We have observed a notably greater level of interest in our biologics platform, especially regarding high concentration subcutaneous delivery, from numerous large pharmaceutical companies and top biotechs around the world. This may partly stem from the news surrounding Elektrofi, but it also reflects the ongoing public presentations we deliver about our technology. We currently have work underway in this area aimed at demonstrating the technology's value in biology, and we look forward to discussing those results over the next few months. When visitors have come to our manufacturing facility in Helsinki — from the U.S., from Europe, and from other regions — they have been very impressed by Nanoform's capacity to scale our technology. They regard this as a possible edge over the competition, along with the robustness, the high yields our technology achieves, and the capability to scale up to commercial manufacturing. They have witnessed what we accomplished with the small molecule technology. They have seen the engineering strength that exists within Nanoform, and they have seen that we can already show significant scale with this manufacturing technology, which has given them strong confidence that Nanoform's technology genuinely stands out in the competitive landscape when it comes to potentially bringing these drugs to the market in the future.

Christian Jones executive
#22

It's a really exciting space to be in—one we're deeply involved with, and hopefully we'll have more announcements before long. Moving on to what's happening in the pharma market: we've been quite busy this year, especially over the past couple of months. This stretch is basically the biggest conference season for pharma. We gave presentations at PODD in Boston, where I spoke together with Takeda about our updates in 2 areas—high concentration bio and lung delivery of biologics. There's a lot of interest there, as I already noted. On other fronts, we attended BioEurope in Vienna and CPHI in Frankfurt only a couple of weeks back. Key CDMO peers—I brought this up earlier—have verified weak project counts in small molecule early development outsourcing. That lines up closely with our own observations. The volume of proposals we've issued annually is the highest it's ever been, though decisions are taking longer. We're hopeful that this will soon become apparent and that a portion of those proposals will begin to convert, giving us a substantial rise in signed projects over the months ahead.

Christian Jones executive
#23

But the industry is in flux. Big pharma companies are cutting a lot of staff right now. On top of that, many of the things that shaped the pharma landscape 2 to 3 years back — VC investors holding off on funding very early-stage projects at their biotech companies and concentrating on late-stage assets — have created a kind of deficit in the preclinical landscape. So that, I think, is another contributing factor. Even so, Nanoform has been having active conversations with a great many companies, and people recognize real value in our technology. So we're eagerly anticipating this uptick, which we expect soon. Also, the biosimilar landscape has changed somewhat lately. Just over a month ago, the regulatory approval pathway for biosimilars changed. That has now raised interest in the space among biosimilar developers, since getting these products to market is now quicker and less costly. Before, launching a biosimilar was a huge hurdle — EUR 120 million to EUR 150 million for an oncology product are not unusual figures, versus EUR 5 million to EUR 10 million in the small molecule space for generics.

Christian Jones executive
#24

Biosimilars, meanwhile, are now seeing development costs in the range of EUR 30 million to EUR 50 million. That has generated considerably more interest in this area. So watching how that unfolds would be quite fascinating, especially when it comes to technologies we hold internally, which could be of interest. As I also noted on my opening slide, we have broadened our market footprint, with excellent relationships built with CBC, a company boasting more than 100 years of history in Japan and one of the country's top distributors. And we have managed to establish a very robust presence in the territory at major pharmaceutical conferences and at very specific formulation events. We are beginning to see that effort bear fruit, with plenty of projects and interest coming through. In Korea, too, we have observed notable interest. Only last week, we held a business meeting in Korea, where we visited numerous companies. And it is evident that Korea is a nation centered on innovation, centered on biologics innovation, and it also holds a strong interest in the product kernel space that we occupy. So with that, I will conclude the commercial session now, and thank you for your time.

Henri von Haartman executive
#25

Thanks, Christian. Henri here from IR. On December 16, we're holding our Capital Markets Day in Helsinki. Everyone is very welcome to attend. Seats are limited. So tomorrow we'll put out the invite via PR, and that release will include instructions on how to sign up. Should you have any questions, the simple way to get in touch — and simple to remember — is ir@nanoform.com. I'll now begin the Q&A session. One moment, please.

Operator operator
#26

<<operator_script>> Our following question is from Christopher at SEB.

Christopher Uhde analyst
#27

Alright, I have 2. Starting with the first one, I want to begin by congratulating you on the GMP license — that's a big achievement. Johanna, what could you share with us regarding your preparations for FDA GMP inspections? I suppose the backdrop here is that, generally speaking, the FDA seems to set the bar somewhat higher than other regulators do. We often see companies receive rejections due to manufacturing observations, even when those drugs have already been approved in other markets. So what are your thoughts on that? That's my first question.

Johanna Kause executive
#28

Thanks for that question, and thanks as well for the congratulations — much appreciated. So alongside the work we're doing now to get ready for the commercial license, we've had a program in place for some time already to prepare for the FDA. We understand that the EU regulators and the FDA are not the same, and naturally we want to be properly prepared. So what we're focused on is, naturally, training our people and making sure our capabilities are in place. We run simulations, for instance. We carry out what are known as mock inspections. And then, beyond that, one of the main things — one of the big things — we do is examine our own supply chain for every critical material, naturally the raw material API, or bulk API, as we call it. We conduct audits of our partners and our service providers and, broadly speaking, make sure our quality management system also accounts for any FDA requirements that may differ or, let's say, are more stringent, stricter than what the EU requires. As we understand it, we could potentially face an FDA inspection at the point when the marketing authorization application has been submitted in the United States.

Johanna Kause executive
#29

We’re also getting ready specifically for a pre-approval inspection from that angle.

Christopher Uhde analyst
#30

My second question is probably directed at Peter. From a financial modeling standpoint, how should we think about the different kernels? I mean, is it sort of — are you looking at doing deals where it's basically copy and paste on the sort of financial final terms of the kind of aggregate agreements, recognizing, obviously, that you have this deal mosaic that you need to work out?

Edward Haeggstrom executive
#31

Albert, why don't you start things off on this one, and then Peter can pick it up from there.

Albert Haeggstrom executive
#32

Yes. So Christopher, what we're doing is, of course, as you know, since our technology is new, we don't want to add to the hurdle — potential hurdles — by having a different business model. So in that sense we're very business model friendly, in that we use the industry norms. And as you know, the industry has very old and very good and very worked out models for biotechs and for service providers and for — even for kernels. So we don't create anything new. When we talk to clients, we talk in the language that they are very familiar with. One other aspect, of course, is that when the cost of capital for Nanoform was clearly lower than it is today and the money was free and so forth from the central banks, our thinking was more that it is okay for us to take the bigger upside a little bit later, meaning after launch and so forth. During the last 2 years, we have been focusing more on finding partners and choosing business models where we spend less money upfront. And that is, of course, a very important thing. So we are prepared to — if the clients or the partners fund a lot or even all of the development costs, then we are, of course, giving away a little bit of the upside.

Albert Haeggstrom executive
#33

And I think that's just reasonable. And that's what's visible now when you look at the first deals we completed versus the most recent ones. And also, if you happen to be a bigger company or even a major pharma, your WACC or capital return requirements are clearly lower than those of a smaller player. So they're pleased with this situation as well. That's my take. Peter, anything you'd like to add?

Peter Hänninen executive
#34

No, I think one thing that's maybe worth remembering is that even though we license the IP tied to a particular product, the spinout still has Nanoform doing the manufacturing. So whatever happens to the kernel further down the line, production stays at our facility, and beyond the stake we hold in the asset plus the royalty, the milestones, and the profit shares, we'll also see manufacturing revenue flowing to us.

Albert Haeggstrom executive
#35

And I might add to that: sure, given that we haven't yet demonstrated meaningful milestone payments or meaningful revenue, that doesn't make it impossible to achieve. It just reflects how the industry operates — during the preclinical stage, the amounts involved are fairly modest. Once you reach the clinic and move nearer to a market launch, you see very large increases in the values shared and in the size of deals you're able to sign. And of course, you know what sorts of deals are possible in this industry. There, I'd like to give an example — one recent case, of course, is Halozyme's acquisition of Elektrofi, which remains in the preclinical stage, more or less.

Operator operator
#36

That brings us to the end of the Q&A. I'll now return the floor to the speakers for any final remarks.

Henri von Haartman executive
#37

Thanks, operator. For Nanoform, I want to express appreciation to everyone who joined us today. Should you have further questions, please don't hesitate to get in touch with us. We hope each of you enjoys a wonderful Wednesday afternoon and evening. Thanks, and goodbye.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Nanoform Finland Oyj transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Nanoform Finland Oyj earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.